Molecule Indication China Ph3 / Pivotal Global Status
Planning Enrollment
OncologySacituzumab
govitecan
(Trodelvy)
mTNBC (3L)
BLA approved in US
HR+, HER2- (3L)
Phase 3
mUC (2/3L)
Phase 2/3(1)
mTNBC (1L)
Phase 2
Asia basket trial
-
FGF401HCC
Phase 1/2
ImmunologyEtrasimodUlcerative colitis
Phase 3
Other autoimmune diseases
(CD, AD)
Phase 2/3(2)
Cardio-Renal
Disease
NefeconlgA nephropathy
Phase 3
RalinepagPAH
Phase 3
Infectious
Disease
Eravacycline
(Xerava)
cIAI
NDA approved in US, EU and Singapore
Taniborbactam
(VNRX-5133)
cUTI
Phase 3
SPR206Gram negative infections
Phase 1

Abbreviations: mTNBC = metastatic triple-negative breast cancer; HR+/HER2- = hormone receptor-positive/human epidermal growth factor receptor 2-negative; mUC = metastatic urothelial cancer; HCC = hepatocellular carcinoma; CD = Crohn’s disease; AD = atopic dermatitis; IgA = immunoglobulin A; PAH = pulmonary arterial hypertension; cIAI = complicated intra-abdominal infections; cUTI = complicated urinary tract infections; IND = investigational new drug; BLA = biologics license application; NDA = new drug application; 1L = first-line of treatment; 2L = second- line of treatment; 3L = third-line of treatment.
Notes: 
(1) Phase 2 trial for mUC is a pivotal trial. 
(2) Arena is conducting a Phase 2/3 program for CD and a Phase 2b program for AD.
 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers